Artrya signs five-year HonorHealth agreement worth a minimum US$0.5 million
Artrya Limited (ASX: AYA) has entered a five-year commercial agreement with Arizona health system HonorHealth, with a minimum contracted value of US$0.5 million. The agreement covers Artrya’s Salix® AI-powered cloud platform for the assessment and management of coronary artery disease.
HonorHealth becomes Artrya’s fifth U.S. commercial customer and its first inbound customer secured outside the company’s foundation customers and SAPPHIRE study participants. It is also Artrya’s second largest customer, and the agreement follows the recent Huntsville commercial agreement.
John Konstantopoulos, Co-Founder and CEO of Artrya
“The HonorHealth agreement is another major step forward in our U.S. commercial roll-out and, importantly, represents our first inbound U.S. customer…”
Mr Konstantopoulos said the agreement comes shortly after Huntsville Health became the first SAPPHIRE study partner to convert to a commercial customer. In his words, this “demonstrates growing awareness of Salix® and commercial momentum across multiple channels of our U.S. strategy.”
Key points of the agreement and the customer:
- A five-year term with a minimum contracted value of US$0.5 million.
- Nine acute-care hospitals providing coronary CT angiography (CCTA).
- 40 cardiac specialist offices supported through HonorHealth Heart Care.
- A population served of approximately five million people.
When big ASX news breaks, our subscribers know first
How the agreement generates revenue
Under the agreement, Salix® Coronary Anatomy will generate recurring SaaS subscription revenue. The US$0.5 million minimum contracted value relates to Salix® Coronary Anatomy only.
Additional fee-per-scan revenue comes from CCTA assessments performed with Salix® Coronary Plaque and, following FDA clearance, Salix® Coronary Flow. This potential usage-based revenue is not included in the minimum.
Artrya’s FY26 financial results put Coronary Flow at a US$877 CPT reimbursement rate, the highest-value module, with FDA clearance targeted by the end of calendar 2026.
| Module | Revenue type | Included in US$0.5M minimum | Status |
|---|---|---|---|
| Salix® Coronary Anatomy | Recurring SaaS subscription | Yes | n/a |
| Salix® Coronary Plaque | Fee-per-scan | No | n/a |
| Salix® Coronary Flow | Fee-per-scan | No | FDA clearance required |
Contract terms outlined by the company:
- A 5-year term.
- Standard provisions for events of default.
- Customary terms covering security and privacy protocols, support levels and software upgrades.
What CCTA is and why a large health system matters
Coronary CT angiography, or CCTA, is a scan that uses computed tomography imaging to examine the arteries supplying the heart. Salix® analyses these scans in the cloud to support real time, point of care assessment and management of coronary artery disease.
HonorHealth is a top 100 U.S. health system. Salix® will be deployed across the hospitals within its network that provide CCTA, which Artrya said extends its U.S. commercial footprint and provides another large reference customer to help broader market adoption.
Dr. Joshua Kim, D.O., Network Director of Advanced Medical Imaging at HonorHealth, explained the selection of Salix®:
Dr. Joshua Kim, D.O., Network Director of Advanced Medical Imaging, HonorHealth
“These are the reasons we have selected Salix® over other technologies we considered, to seamlessly and more effectively manage our growing clinical workflows of patients with coronary artery disease. We also see strong benefits from the way Salix® can support earlier and more precise decisions to better manage our patients.”
Before the agreement, the Artrya engagement team, which included technical, clinical and I.T. disciplines, worked through a detailed Salix® demonstration and validation stage within HonorHealth Heart Care. That stage was led by Dr. Kim.
Building a cardiovascular imaging Centre of Excellence in Arizona
HonorHealth has outlined an ambition to develop a leading CCTA program in Arizona. The proposed pathway envisages an initial focus on embedding Salix® into clinical workflows, followed by growth in physician adoption, CCTA capacity and use of the platform’s coronary assessment modules.
The rollout at Northeast Georgia Health System offers a preview of that sequence, with Salix® processing live patient scans at one of five hospitals and generating revenue from two modules.
Over the longer term, HonorHealth and Artrya intend to explore the development of a recognised cardiovascular imaging Centre of Excellence. It could potentially support real-world clinical evidence, education, training and a reference model for broader U.S. adoption.
HonorHealth is also the primary clinical affiliate of the Arizona State University (ASU) John Shufeldt School of Medicine and Medical Engineering, which the company described as a potential pathway for collaborative AI research and development.
HonorHealth is one of Arizona’s largest non-profit healthcare systems, with:
- 200 primary, specialist and urgent care locations across Arizona.
- More than 17,000 team members.
- 4,000 medical staff.
- The HonorHealth Research Institute.
Mr Konstantopoulos said Artrya’s immediate focus is “on successful implementation and driving clinical adoption across the HonorHealth network.”
Want Alerts Like This on the Healthcare Stocks You Follow?
StockWire X Market Intelligence scores every announcement in our coverage for how significant it’s likely to be for investors, and which way it points, then alerts you on the stocks you follow. The first 1,000 founding members lock in 50% off for life: A$247 a year instead of the standard A$495. Join the founding waitlist today.